Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,886.24
(
1.02%
)
US TECH 100
24,738.00
(
1.21%
)
Dow Jones
48,218.25
(
0.63%
)
Brent Oil
95.03
(
-0.46%
)
Bitcoin
74,417.68
(
-0.11%
)
News Focus
News Focus
Post# of 257403
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122865
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 254844

Tuesday, 02/24/2026 9:47:26 AM

Tuesday, February 24, 2026 9:47:26 AM

Post# of 257403
NOVO reports phase-2 data_on “triple G” candidate, UBT251:

https://www.fiercebiotech.com/biotech/novo-nordisks-triple-g-candidate-drives-20-weight-loss-phase-2-china

https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916503

https://doc.irasia.com/listco/hk/unitedlab/announcement/a260224.pdf

NVO licensed the ex-China commercial rights to UB225151 from China’s United Laboratories one year ago (#msg-175967769). UBT251 hits the same three targets (GLP-1, GIP, and glucoagon) as LLY’s retatrutide. NVO and United’s PRs today have topline data from a phase-2 trial of UBT251 in China. The full dataset will be presented at an unspecified medical conference.

NVO has on ongoing phase-2 trial of UBT251 in North America.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today